September 5, 2022
Archimica continues Expansion – Announces completion of its 2 Mio. Euro Investment Upgrade of its Multi-Purpose Manufacturing Capacity
Archimica has started the operation of its state-of-the art multi-purpose manufacturing capacity at its Lodi (Italy) site. The recent investment has further upgraded the company´s GMP capabilities and its overall 175 m3 highly flexible reactor capacity to realize API and GMP Building Block custom process development and manufacturing projects from 10 kgs to multiple tons through to hundreds of tons from September 2022 on. The investment comprises a range of reactor and separation equipment capabilities, with a total investment volume of more than 2 Mio. Euro.
“With this upgrade and after its close to 10 Mio. Euro investment in our development and manufacturing capabilities during the last 3 years, we are continuing our path to offer expanded state-of-the art small to large volume multi-step custom manufacturing options applying Archimica´s unique chemical reaction technology portfolio to the benefit of our customers worldwide. Archimica’s experienced and flexible team, our broad permit and state-of-the-art environmental protection facilities enable us to industrialize products and processes with the most challenging reagents and reactions known with short lead times to accelerate drug development and supply for complex multi-step APIs into all clinical and commercial stages”, said Ralf Pfirmann, Executive Chairman of Archimica.
Archimica is a leading organization specialized for more than 70 years in active pharmaceutical ingredients (APIs) development and manufacture for the benefit of customers and patients worldwide. Its site in Lodi, Italy operates in compliance with the most recent GMP guidelines and has been successfully inspected by US-FDA, AIFA and numerous other regulatory agencies.
Archimica offers custom synthesis of late stage intermediates and APIs for the innovative and the generic pharmaceutical industry in addition to its range of standard care generic APIs for a broad range of therapeutic areas. Its offering covers highly flexible, agile small clinical stage to continuously improving large commercial manufacturing as well as process development, analytical, quality and regulatory services.
Archimica employs more than 125 staff members which achieve annual revenues of more than 40 Mio. €. Since 2019 Archimica is a fully owned portfolio company of Livia Corporate Development SE.
For more information, visit https://www.archimica.com.
Ediola Rrapaj email@example.com